Momelotinib

The FDA approved momelotinib for treatment of patients with myelofibrosis and anemia regardless of prior myelofibrosis therapy.

In this video, Aaron T. Gerds, MD, MS, discussed the backstory behind an abstract presented at ASCO Annual Meeting, examining a new compound directly targeting the ACVR1 gene in order to improve anemia in patients with myelofibrosis.

NEW ORLEANS — In this video, Aaron T. Gerds, MD, MS, assistant professor at the Cleveland Clinic Taussig Cancer Institute, discusses updated results from the Momentum phase 3 study presented at the ASH Annual Meeting and Exposition.

Aaron T. Gerds, MD, MS, spoke with Healio about the randomized phase 3 MOMENTUM study.

CHICAGO — In a video interview, Aaron Thomas Gerds, MD, MS, discussed the efficacy and safety of momelotinib in a subset of patients with thrombocytopenic myelofibrosis from the MOMENTUM study, which was presented at ASCO Annual Meeting.

CHICAGO — Aaron Thomas Gerds, MD, MS, of Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, spoke with Healio about topline results from the MOMENTUM study presented at ASCO Annual Meeting.

Momelotinib demonstrated statistically significant improvement in anemia measures, splenic response and total symptom score compared with danzol among patients with previously treated myelofibrosis, according to study results.

A randomized phase 3 trial of momelotinib for patients with pretreated myelofibrosis met all primary and key secondary endpoints, according to topline data released by the agent’s manufacturer.